Skip to the page

Data / Drug companies / Bioverativ Therapeutics Inc.

Bioverativ Therapeutics Inc.: 22 products in the FDA NDC directory, labeler code 71104

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Bioverativ Therapeutics Inc. (labeler code 71104) lists 22 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 16 plasma derivatives, 6 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on February 22, 2023.

The request: Watch Bioverativ Therapeutics Inc. (FDA labeler code 71104): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
71104
Products in commercial distribution
22
Packages
22
Finished drugs by generic name
2
Prescription products
6
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
May 5, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)22100%

Products by type

TypeProductsShare
Plasma derivatives1672.7%
Prescription drugs627.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Antihemophilic factor (recombinant), fc fusion protein101
Coagulation factor ix (recombinant), fc fusion protein61

Dosage forms

Dosage formProductsShare
Kit22100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Altuviiio71104-984KitBiologics (BLA)February 22, 2023
Altuviiio71104-983KitBiologics (BLA)February 22, 2023
Altuviiio71104-982KitBiologics (BLA)February 22, 2023
Altuviiio71104-981KitBiologics (BLA)February 22, 2023
Altuviiio71104-979KitBiologics (BLA)February 22, 2023
Altuviiio71104-978KitBiologics (BLA)February 22, 2023
Eloctate71104-810KitBiologics (BLA)September 6, 2017
Eloctate71104-809KitBiologics (BLA)September 6, 2017
Eloctate71104-808KitBiologics (BLA)September 6, 2017
Eloctate71104-807KitBiologics (BLA)September 6, 2017
Eloctate71104-806KitBiologics (BLA)September 6, 2017
Eloctate71104-805KitBiologics (BLA)September 6, 2017
Eloctate71104-804KitBiologics (BLA)September 6, 2017
Eloctate71104-803KitBiologics (BLA)September 6, 2017
Eloctate71104-802KitBiologics (BLA)September 6, 2017
Eloctate71104-801KitBiologics (BLA)September 6, 2017
Alprolix71104-977KitBiologics (BLA)May 5, 2014
Alprolix71104-966KitBiologics (BLA)May 5, 2014
Alprolix71104-944KitBiologics (BLA)May 5, 2014
Alprolix71104-933KitBiologics (BLA)May 5, 2014
Alprolix71104-922KitBiologics (BLA)May 5, 2014
Alprolix71104-911KitBiologics (BLA)May 5, 2014

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.